Lee Jooho, Seo Kyoung-Woo, Park Jin-Sun, Yang Hyoung-Mo, Lim Hong-Seok, Choi Byoung-Joo, Choi So-Yeon, Yoon Myeong-Ho, Hwang Gyo-Seung, Tahk Seung-Jae, Shin Joon-Han
Division of Cardiology, Department of Internal Medicine, Seoul Medical Center, Seoul, Republic of Korea.
Department of Cardiology, Ajou University School of Medicine, Suwon, Republic of Korea.
Cardiol Res Pract. 2020 Nov 10;2020:8885518. doi: 10.1155/2020/8885518. eCollection 2020.
Limited data are available to support an invasive treatment strategy in nonagenarians with acute myocardial infarction (AMI). We aimed to investigate whether percutaneous coronary intervention (PCI) is beneficial in this frail population.
We retrospectively analyzed 41 nonagenarians with AMI (both ST-segment-elevation and non-ST-segment-elevation MI) between 2006 and 2015 in a single center. We assessed 30-day and one-year mortality rates according to the treatment strategy.
Among study subjects, 24 (59%) were treated with PCI (PCI group) and 17 (41%) were treated with conservative management (medical treatment group) per the clinician's discretion. The median follow-up duration was 30 months (0-74 months). Thirty-day mortality was lower in the PCI group than in the medical treatment group (17% vs. 65%; < 0.001). One-year mortality was also lower in the PCI group than in the medical treatment group (21% vs. 76%; < 0.001). The PCI group presented a 73% decreased risk of death (adjusted hazard ratio: 0.269; 95% confidence interval: 0.126-0.571; < 0.001). In the Killip class 1 through 3 subgroups ( = 36), 30-day and one-year mortality were still higher among those in the medical treatment group (13% vs. 54% at 30 days; < 0.001 and 17% vs. 69% at one year; < 0.001). Landmark analysis after 30 days revealed no significant difference in the cumulative mortality rate between the two groups, indicating that the mortality difference was mainly determined within the first 30 days after AMI.
Mortality after AMI was decreased in correlation with the invasive strategy relative to the conservative strategy, even in nonagenarians. Regardless of age, PCI should be considered in AMI patients. However, large-scale randomized controlled trials are needed to support our conclusion.
支持对急性心肌梗死(AMI)的非agenarians采取侵入性治疗策略的数据有限。我们旨在研究经皮冠状动脉介入治疗(PCI)在这一脆弱人群中是否有益。
我们回顾性分析了2006年至2015年在单一中心的41例患有AMI(包括ST段抬高型和非ST段抬高型心肌梗死)的非agenarians。我们根据治疗策略评估了30天和1年的死亡率。
在研究对象中,根据临床医生的判断,24例(59%)接受了PCI治疗(PCI组),17例(41%)接受了保守治疗(药物治疗组)。中位随访时间为30个月(0 - 74个月)。PCI组的30天死亡率低于药物治疗组(17%对65%;<0.001)。PCI组的1年死亡率也低于药物治疗组(21%对76%;<0.001)。PCI组的死亡风险降低了73%(调整后的危险比:0.269;95%置信区间:0.126 - 0.571;<0.001)。在Killip 1至3级亚组(n = 36)中,药物治疗组的30天和1年死亡率仍然较高(30天时为13%对54%;<0.001,1年时为17%对69%;<0.001)。30天后的标志性分析显示两组之间的累积死亡率没有显著差异,表明死亡率差异主要在AMI后的前30天内确定。
即使在非agenarians中,相对于保守策略,与侵入性策略相关的AMI后死亡率也有所降低。无论年龄如何,AMI患者都应考虑PCI治疗。然而,需要大规模随机对照试验来支持我们的结论。